Indivior Pharmaceuticals (INDV) EBT (2024 - 2026)

Indivior Pharmaceuticals' EBT history runs 3 years deep, the most recent figure standing at $115.0 million for Q1 2026.

• On a quarterly basis, EBT rose 94.92% year-over-year to $115.0 million in Q1 2026; TTM through Mar 2026 was $295.0 million, a 4816.67% increase from a year earlier, with the FY2025 full-year figure at $239.0 million, up 1095.0% from the prior year.
• EBT grew to $115.0 million in Q1 2026 per INDV's latest filing, from $81.0 million in the prior quarter.
• Across five years, EBT topped out at $115.0 million in Q1 2026 and bottomed at -$121.0 million in Q2 2024.
• The 3-year median for EBT is $59.0 million (2025), against an average of $41.6 million.
• Biggest YoY gain for EBT was 151.24% in 2025; the steepest drop was 19.18% in 2025.
• Year by year, EBT stood at $38.0 million in 2024, then soared by 113.16% to $81.0 million in 2025, then soared by 41.98% to $115.0 million in 2026.
• Per Business Quant, the three latest INDV EBT figures stand at $115.0 million (Q1 2026), $81.0 million (Q4 2025), and $37.0 million (Q3 2025).